Emerging antiviral drugs (Q56786308)

Expert Opinion on Emerging Drugs

Europe PubMed Central

title

Emerging antiviral drugs (English)

0 references

Erik De Clercq

1

0 references

language of work or name

English

0 references

publication date

September 2008

0 references

published in

0 references

volume

13

0 references

issue

3

0 references

page(s)

393-416

0 references

cites work

Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

The design of drugs for HIV and HCV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

HIV drug development: the next 25 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Interferons at age 50: past, current and future impact on biomedicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

The way forward in HCV treatment--finding the right path

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Antiviral agents active against influenza A viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

The war against influenza: discovery and development of sialidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Antivirals and antiviral strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Polyomavirus-associated nephropathy: update on antiviral strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

N6-methyl-AMP aminohydrolase activates N6-substituted purine acyclic nucleoside phosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

A high capacity assay for inhibitors of human papillomavirus DNA replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Biphenylsulfonacetic acid inhibitors of the human papillomavirus type 6 E1 helicase inhibit ATP hydrolysis by an allosteric mechanism involving tyrosine 486

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

High Frequency of Spontaneous Helicaseprimase Inhibitor (BAY 57–1293) Drug-Resistant Variants in Certain Laboratory Isolates of HSV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Antiviral drugs for cytomegalovirus diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

In search of effective anti-HHV-6 agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Activation of human herpesviruses 6 and 7 in patients with chronic fatigue syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

The acyclic nucleoside phosphonates from inception to clinical use: historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Efficacy of cidofovir in a murine model of disseminated progressive vaccinia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

A case of human orf in an immunocompromised patient treated successfully with cidofovir cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Smallpox vaccine. A tame virus runs amok

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

The history of N-methanocarbathymidine: the investigation of a conformational concept leads to the discovery of a potent and selective nucleoside antiviral agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Antiviral therapy of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

New developments in the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Entecavir: a new treatment option for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

The HBV drug entecavir - effects on HIV-1 replication and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Telbivudine: a new option for the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Antiviral activities of novel 5-phosphono-pent-2-en-1-yl nucleosides and their alkoxyalkyl phosphonoesters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

A large vaccine-derived poliovirus outbreak on Madura Island--Indonesia, 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Potential use of antiviral agents in polio eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

21 January 2018

Rhinovirus chemotherapy

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Anti-enterovirus activity and structure–activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo[3,4-a]benzimidazoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Anti-influenza virus agents: synthesis and mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Current and future antiviral therapy of severe seasonal and avian influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Anti-influenza virus activity of peramivir in mice with single intramuscular injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Mechanism of action of T-705 against influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Respiratory syncytial virus infections: recent prospects for control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

RSV604, a novel inhibitor of respiratory syncytial virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Prospects for antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Acute Encephalitis, a Poliomyelitis-like Syndrome and Neurological Sequelae in a Hamster Model for Flavivirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Activity of T-1106 in a Hamster Model of Yellow Fever Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

A Dengue Fever Viremia Model in Mice Shows Reduction in Viral Replication and Suppression of the Inflammatory Response after Treatment with Antiviral Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

The Mechanism of Action of -D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine Involves a Second Metabolic Pathway Leading to -D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine 5'-Triphosphate, a Potent Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Mechanism of Activation of -D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Anti-HIV activity of (-)-(2R,4R)-1- (2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393

Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.3.393